UroGen Pharma Ltd. (URGN): Total Liabilities
$305.93M
As of 2025-12-31
$384.99M
As of 2026-06-30
+10.8%
3-year compound annual growth
+64.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $305.93M | +3.9% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $294.51M | +20.9% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $243.52M | +8.2% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $224.98M | +102.1% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $111.33M | +334.0% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $25.65M | +16.1% | 2022-03-21, Balance as of period end |
| 2019-12-31 | $22.09M | +64.0% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $13.46M | +91.4% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $7.04M | +4.2% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $6.75M | n/a | 2018-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $305.93M | +3.9% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $130.07M | -6.1% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $78.03M | -37.2% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $23.85M | -11.7% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.91M | -13.7% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $20.65M | -27.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $191.91M | -4.1% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $2.08B | +35.6% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
Compare URGN, ZVRA, ZYME, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗